TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15475021

Group type: EXPERIMENTAL
Intervention: High-intensity-low-frequency exercise (65-75% HRR, 3-4 sessions/week)
Number of subjects: 324

Group type: EXPERIMENTAL
Intervention: High-intensity-high-frequency exercise (65-75% HRR, 5-7 sessions/week)
Number of subjects: 324

Group type: EXPERIMENTAL
Intervention: Moderate-intensity-high-frequency exercise (45-55% HRR, 5-7 sessions/week)
Number of subjects: 324

Group type: COMPARATOR
Intervention: High-intensity-high-frequency vs. moderate-intensity-low-frequency
Number of subjects: 324

Group type: EXPERIMENTAL
Intervention: Intensity effect on insulin
Number of subjects: 324

Group type: EXPERIMENTAL
Intervention: Frequency effect on aerobic fitness
Number of subjects: 324
Study: 11402958

Group type: EXPERIMENTAL
Intervention: iohexol 0.6 ml/kg (G1)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: iohexol 1.2 ml/kg (G2)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: sodium and meglumine diatrizoate 58% 0.6 ml/kg (G3)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: sodium and meglumine diatrizoate 58% 1.2 ml/kg (G4)
Number of subjects: 48
Study: 9114762

Group type: EXPERIMENTAL
Intervention: d,l-sotalol
Number of subjects: 296

Group type: COMPARATOR
Intervention: class I drugs
Number of subjects: 296

Group type: COMPARATOR
Intervention: class I drugs with beta blockers
Number of subjects: 296
Study: 8029263

Group type: EXPERIMENTAL
Intervention: 150 mg caffeine + 2 mg nicotine polacrilex
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: 300 mg caffeine + 4 mg nicotine polacrilex
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Cigarette smoking
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Caffeine administration
Number of subjects: 6

Group type: COMPARATOR
Intervention: Nicotine polacrilex
Number of subjects: 6
Study: 2918192

Group type: EXPERIMENTAL
Intervention: Written MMSE
Number of subjects: 71

Group type: COMPARATOR
Intervention: Standard MMSE
Number of subjects: 71
Study: 31475622

Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (40 IU)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study: 30917420

Group type: COMPARATOR
Intervention: HBP-NLVH group (80 cases)
Number of subjects: 240

Group type: COMPARATOR
Intervention: HBP-LVH group (80 cases)
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Normal control group (80 cases)
Number of subjects: 240

Group type: COMPARATOR
Intervention: Correlation of microRNA-29b with IVSD
Number of subjects: 240

Group type: COMPARATOR
Intervention: Correlation of microRNA-29b with LVPWD
Number of subjects: 240

Group type: COMPARATOR
Intervention: Sensitivity and specificity of serum microRNA-29b levels
Number of subjects: 240
Study: 25943992

Group type: EXPERIMENTAL
Intervention: Neutrophil gelatinase‐associated lipocalin (NGAL)
Number of subjects: 231

Group type: EXPERIMENTAL
Intervention: B-type natriuretic peptide (BNP)
Number of subjects: 231

Group type: EXPERIMENTAL
Intervention: Blood urea nitrogen (BUN)
Number of subjects: 231
Study: 23938095

Group type: EXPERIMENTAL
Intervention: SMILE
Number of subjects: 52

Group type: COMPARATOR
Intervention: FS-LASIK (Control)
Number of subjects: 52
Study: 20949349

Group type: EXPERIMENTAL
Intervention: Norepinephrine infusion at target MAP of 75 mmHg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Norepinephrine infusion at target MAP of 60 mmHg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Norepinephrine infusion at target MAP of 90 mmHg
Number of subjects: 12
Study: 18187617

Group type: EXPERIMENTAL
Intervention: Nicotinic acid (NA) 1 g 60 min before, and 0.5 g 60 and 180 min after sprint 1
Number of subjects: 7

Group type: COMPARATOR
Intervention: Control (Con) trial
Number of subjects: 7
Study: 16303987

Group type: EXPERIMENTAL
Intervention: Medication utilization patterns in patients with BPD
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Methods of suicidality in patients with BPD
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Axis III discharge diagnoses in patients with BPD
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Consideration of overdosage as a means to end life in patients with BPD
Number of subjects: 29
Study: 12745514

Group type: EXPERIMENTAL
Intervention: Metacholine (MCh; 2 and 4 mg/min) and sodium nitroprusside (SNP; 5 and 10 mg/min)
Number of subjects: 108
Study: 11187922

Group type: EXPERIMENTAL
Intervention: American therapy template with two post-remission intensification modules
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Third intensification module
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Intrathecal methotrexate injections
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Age, sex, and white count >50 x 10(9)/l
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Rome/NCI criteria
Number of subjects: 90
Study: 8884642

Group type: EXPERIMENTAL
Intervention: Scaling and root planing plus application of 25% tetracycline fiber (S + Tet)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Scaling and root planing plus application of 2% minocycline gel (S + Min)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Scaling and root planing plus application of 25% metronidazole gel (S + Met)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Scaling and root planing alone (S)
Number of subjects: 54
Study: 1858637

Group type: EXPERIMENTAL
Intervention: Isolated systolic hypertension patients
Number of subjects: 79
Study: 6358652

Group type: EXPERIMENTAL
Intervention: Therapeutic plasmapheresis
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: Pulse therapy
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: Plasmapheresis
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: Anticoagulant treatment
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: Autoantibody-induced RPGN
Number of subjects: 350
Study: 31295222

Group type: EXPERIMENTAL
Intervention: High-risk HPV infection
Number of subjects: 245

Group type: EXPERIMENTAL
Intervention: Persistent high-risk HPV infection
Number of subjects: 245

Group type: EXPERIMENTAL
Intervention: HPV16 and/or HPV18 types
Number of subjects: 245

Group type: EXPERIMENTAL
Intervention: Incident high-risk HPV infection postpartum
Number of subjects: 245

Group type: EXPERIMENTAL
Intervention: Persistent high-risk HPV and preterm birth
Number of subjects: 245
Study: 29059186

Group type: EXPERIMENTAL
Intervention: DEC and albendazole (single oral dose, repeated annually or semi-annually)
Number of subjects: 102
Study: 26943607

Group type: EXPERIMENTAL
Intervention: S100 levels measured on postoperative day 1 (PD1)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: S100 levels <123 pg mL-1 on PD1
Number of subjects: 92
Study: 25726215

Group type: EXPERIMENTAL
Intervention: Monitoring in a sports center (MON)
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Prescription at home (PRES)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Recommendation (REC)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 76
Study: 22994049

Group type: EXPERIMENTAL
Intervention: Oral contraceptive pretreatment (OCP), n = 53
Number of subjects: 85

Group type: COMPARATOR
Intervention: Control group (no OCP), n = 32
Number of subjects: 85
Study: 19923550

Group type: EXPERIMENTAL
Intervention: IV bapineuzumab (0.15, 0.5, 1.0, or 2.0 mg/kg)
Number of subjects: 234

Group type: EXPERIMENTAL
Intervention: IV bapineuzumab
Number of subjects: 234

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 234
Study: 17525395

Group type: EXPERIMENTAL
Intervention: 500 mg of uric acid (UA)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 1000 mg of uric acid (UA)
Number of subjects: 24

Group type: COMPARATOR
Intervention: 5% mannitol/0.1% lithium carbonate (vehicle group)
Number of subjects: 24
Study: 15217656

Group type: EXPERIMENTAL
Intervention: 0.04 mg/kg of midazolam IV 20 minutes preoperatively
Number of subjects: 88

Group type: COMPARATOR
Intervention: Placebo IV 20 minutes preoperatively
Number of subjects: 88
Study: 11277451

Group type: EXPERIMENTAL
Intervention: Coloring a single letter in Stroop tasks
Number of subjects: 312

Group type: EXPERIMENTAL
Intervention: Coloring a single element
Number of subjects: 312
Study: 9736008

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT) of residual symptoms supplemented by lifestyle modification and well-being therapy
Number of subjects: 40

Group type: COMPARATOR
Intervention: Clinical management
Number of subjects: 40
Study: 8623943

Group type: EXPERIMENTAL
Intervention: Macintosh 3 laryngoscope
Number of subjects: 0

Group type: COMPARATOR
Intervention: Miller 2 laryngoscope
Number of subjects: 0

Group type: COMPARATOR
Intervention: Different anesthetists
Number of subjects: 0
Study: 2571295

Group type: EXPERIMENTAL
Intervention: Rilmenidine (1 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Beta‐adrenergic blockers
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Diuretics
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ketanserin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Angiotensin‐converting enzyme inhibitors
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Captopril (100 mg) with Hydrochlorothiazide (25 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pindolol (10 mg) with Clopamide (5 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ketanserin and Flosequinan
Number of subjects: 0
Study: 180192

Group type: EXPERIMENTAL
Intervention: Topical interferon inducer (CP 20961)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Drug vehicle (polysorbate-80 in glycerol and saline)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 6

Group type: COMPARATOR
Intervention: Oral lactose
Number of subjects: 6
Study: 31538913

Group type: EXPERIMENTAL
Intervention: Cellular Matrix combined with autologous platelet‐rich plasma (A‐PRP) and standardized physiotherapy
Number of subjects: 25
Study: 31177276

Group type: EXPERIMENTAL
Intervention: Maternal Multiple Micronutrients (MMN) supplementation
Number of subjects: 108

Group type: COMPARATOR
Intervention: Iron and folic acid (IFA) supplementation
Number of subjects: 108
Study: 27940063

Group type: EXPERIMENTAL
Intervention: Adherence monitoring with customized reminders (including alarms, texts, telephone calls, and/or e‐mails)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Monitoring with customized reminders plus provider notification (every 2 weeks, providers received notification if adherence decreased to <90%)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Wireless pill bottle use alone (control)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 120
Study: 26164799

Group type: EXPERIMENTAL
Intervention: Short-term recipients (STR) group
Number of subjects: 176

Group type: EXPERIMENTAL
Intervention: Long-term recipients group
Number of subjects: 176

Group type: EXPERIMENTAL
Intervention: Shoulder Pain Disability Index
Number of subjects: 176

Group type: EXPERIMENTAL
Intervention: Shoulder Disability Questionnaire
Number of subjects: 176

Group type: EXPERIMENTAL
Intervention: Constant-Murler Score
Number of subjects: 176
Study: 24432674

Group type: EXPERIMENTAL
Intervention: Bushen Tiaojing Recipe (BTR)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Hormone Replacement Therapy (HRT)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: BTR + HRT
Number of subjects: 72
Study: 21175995

Group type: EXPERIMENTAL
Intervention: Rikkunshito (7.5 g day(-1) for 2 weeks)
Number of subjects: 9
Study: 19162498

Group type: EXPERIMENTAL
Intervention: T3 sympathicotomy (n=68)
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: T4 sympathicotomy (n=73)
Number of subjects: 141
Study: 17001567

Group type: EXPERIMENTAL
Intervention: Preoperative ERCP
Number of subjects: 123

Group type: COMPARATOR
Intervention: Intraoperative ERCP
Number of subjects: 123
Study: 16281459

Group type: EXPERIMENTAL
Intervention: Crossover analysis using Troxel et al.'s method
Number of subjects: 0

Group type: COMPARATOR
Intervention: As-treated analysis
Number of subjects: 0
Study: 10661479

Group type: EXPERIMENTAL
Intervention: recombinant human growth hormone (rhGH) 4 IU/m2
Number of subjects: 20

Group type: COMPARATOR
Intervention: placebo injections
Number of subjects: 20
Study: 9104085

Group type: EXPERIMENTAL
Intervention: Practical interventions in preventing major causes of morbidity and mortality in older women
Number of subjects: 164500
Study: 8350309

Group type: EXPERIMENTAL
Intervention: Supplementary clinical instruction by general internal medicine physicians
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Supplementary clinical instruction by physical therapists
Number of subjects: 0

Group type: COMPARATOR
Intervention: Baseline education (lecture and supervision by clinical preceptors)
Number of subjects: 0
Study: 3513642

Group type: EXPERIMENTAL
Intervention: 750 mg mefloquine, 1.5 g sulfadoxine, 75 mg pyrimethamine (MSP)
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: 600 mg quinine 8‐hourly for 3 days and 500 mg tetracycline 8‐hourly for 7 days (Q3T7)
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: 600 mg quinine 8‐hourly for 7 days and 500 mg tetracycline 8‐hourly for 7 days (Q7T7)
Number of subjects: 119
Study: 31925727

Group type: EXPERIMENTAL
Intervention: Laparoscopic Roux-en-Y gastric bypass (RYGB)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Sleeve gastrectomy (SG)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Conventional treatment with diet and exercise (Control)
Number of subjects: 40
Study: 29275850

Group type: EXPERIMENTAL
Intervention: ProRoot Mineral Trioxide Aggregate (MTA)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Biodentine
Number of subjects: 59
Study: 27523186

Group type: EXPERIMENTAL
Intervention: Bimuno-galactooligosaccharide (B-GOS) 5.5 g/d for 3 weeks
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: B-GOS
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 24062227

Group type: EXPERIMENTAL
Intervention: Single dose of 30 mg/kg TXA on induction of surgery (one shot [OS] group)
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: Loading dose of 10 mg/kg TXA followed by continuous infusion of 2 mg/kg per hour for 20 hours (one day [OD] group)
Number of subjects: 164

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 164
Study: 22721377

Group type: EXPERIMENTAL
Intervention: Tactile stimulation at 20 Hz and 100 Hz
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tactile stimulation at 3 Hz
Number of subjects: 0

Group type: COMPARATOR
Intervention: Tactile stimulation with visual task
Number of subjects: 0
Study: 20104197

Group type: EXPERIMENTAL
Intervention: Conventional treatment plus lower‐molecular weight heparin treatment (LT group)
Number of subjects: 265

Group type: COMPARATOR
Intervention: Conventional treatment (C group)
Number of subjects: 265
Study: 18557664

Group type: EXPERIMENTAL
Intervention: 400 microg B(12) + 2 mg folic acid + 25 mg B(6) per day
Number of subjects: 299

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 299
Study: 15949922

Group type: EXPERIMENTAL
Intervention: 1000 mg sodium valproate
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: 900 mg lithium
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study: 11799348

Group type: EXPERIMENTAL
Intervention: Interferon-alpha (IFN-alpha) 3-6 million units subcutaneously three to six times a week for 6 months
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Interferon-alpha (IFN-alpha)
Number of subjects: 18
Study: 10223267

Group type: EXPERIMENTAL
Intervention: C+E (375 mg caffeine and 75 mg ephedrine)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9

Group type: COMPARATOR
Intervention: Control
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: C+E (D1 and D2 trials)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: C+E
Number of subjects: 9
Study: 7752319

Group type: EXPERIMENTAL
Intervention: Modified Dornier HM3 lithotriptor
Number of subjects: 198

Group type: COMPARATOR
Intervention: MFL 5000 lithotriptor
Number of subjects: 198
Study: 1968710

Group type: EXPERIMENTAL
Intervention: Bucindolol
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 349684

Group type: EXPERIMENTAL
Intervention: Amalgam
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Epoxydent
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Adaptic
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Concise Cap
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Functional cusps (overall observation)
Number of subjects: 4
Study: 31911072

Group type: EXPERIMENTAL
Intervention: Dual continuous theta burst stimulation (cTBS) over left inferior frontal gyrus (IFG‐L) and right inferior parietal gyrus (IPL‐R)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Single site IPL‐R cTBS
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Dual cTBS
Number of subjects: 46

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Single site IFG‐L cTBS
Number of subjects: 46
Study: 28166861

Group type: EXPERIMENTAL
Intervention: Dignity therapy (DT) + standard palliative care (SPC)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Standard palliative care (SPC)
Number of subjects: 80
Study: 25640411

Group type: EXPERIMENTAL
Intervention: Ranibizumab treatment
Number of subjects: 65
Study: 23930866

Group type: EXPERIMENTAL
Intervention: Ketamine 0.5 mg/kg
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Ketamine 1 mg/kg
Number of subjects: 75

Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 75
Study: 21675876

Group type: EXPERIMENTAL
Intervention: Smoking cessation program with exercise (nicotine replacement therapy, behavioral counseling, exercise prescription)
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Smoking cessation program with exercise
Number of subjects: 130
Study: 19131322

Group type: EXPERIMENTAL
Intervention: Self-etching adhesive treatment
Number of subjects: 0
Study: 16925377

Group type: EXPERIMENTAL
Intervention: Heated-humidified carbon dioxide insufflation
Number of subjects: 50

Group type: COMPARATOR
Intervention: Cold-dry carbon dioxide insufflation
Number of subjects: 50
Study: 15673999

Group type: EXPERIMENTAL
Intervention: Moderate dose multivitamin/mineral supplement
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group of typical children
Number of subjects: 20
Study: 11201778

Group type: EXPERIMENTAL
Intervention: Topical tobramycin 0.3%
Number of subjects: 43

Group type: COMPARATOR
Intervention: Topical ofloxacin 0.3%
Number of subjects: 43
Study: 9010042

Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy comprising cyclophosphamide, doxorubicin and oral ftorafur (CAFt) with tamoxifen
Number of subjects: 211

Group type: COMPARATOR
Intervention: Adjuvant chemotherapy comprising cyclophosphamide, doxorubicin and oral ftorafur (CAFt) without tamoxifen
Number of subjects: 211
Study: 8504495

Group type: EXPERIMENTAL
Intervention: Grade 3 TIMI perfusion
Number of subjects: 298

Group type: COMPARATOR
Intervention: Grade 2 TIMI perfusion
Number of subjects: 298

Group type: COMPARATOR
Intervention: Grades 0/1 TIMI perfusion
Number of subjects: 298
Study: 3113222

Group type: EXPERIMENTAL
Intervention: 30 mg of rt-PA
Number of subjects: 123

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Both groups combined
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Patients with patent arteries on both previous angiograms
Number of subjects: 123
Study: 31307836

Group type: EXPERIMENTAL
Intervention: Red blood cell (RBC) transfusion
Number of subjects: 60
Study: 30291280

Group type: EXPERIMENTAL
Intervention: mid-VLPFC target (rTMS at left pars triangularis)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: parietal target (rTMS at left AG)
Number of subjects: 0

Group type: COMPARATOR
Intervention: placebo control (rTMS at somatosensory cortex)
Number of subjects: 0
Study: 26836245

Group type: EXPERIMENTAL
Intervention: 10 μg vaginal E2 softgel capsules
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 24634444

Group type: EXPERIMENTAL
Intervention: Eccentric exercise (n = 60)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Concentric exercise (n = 60)
Number of subjects: 120
Study: 24627787

Group type: EXPERIMENTAL
Intervention: Olanzapine 2.5mg
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Olanzapine 5mg
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Olanzapine (both doses)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Olanzapine and Placebo
Number of subjects: 23
Study: 20070250

Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg daily for 3 months (statin‐treated, ST n=39)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Previous therapy (statin‐free, SF)
Number of subjects: 56
Study: 19026203

Group type: EXPERIMENTAL
Intervention: Two axial Kirschner wire fixation (Group I)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Two axial and supplementary transverse Kirschner wire fixation (Group II)
Number of subjects: 65
Study: 16002492

Group type: EXPERIMENTAL
Intervention: Navigation group (3D computer-assisted localization)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Feedback group (therapist feedback localization)
Number of subjects: 50
Study: 12832372

Group type: EXPERIMENTAL
Intervention: Electro-acupuncture (EA) plus a paracervical block (PCB)
Number of subjects: 286

Group type: COMPARATOR
Intervention: alfentanil plus a paracervical block (PCB)
Number of subjects: 286
Study: 10392878

Group type: EXPERIMENTAL
Intervention: Transdermal patches of estradiol‐17beta
Number of subjects: 6

Group type: COMPARATOR
Intervention: Matched placebo
Number of subjects: 6
Study: 8730807

Group type: EXPERIMENTAL
Intervention: Watching motion-defined static and moving objects
Number of subjects: 0
Study: 1669587

Group type: EXPERIMENTAL
Intervention: Budesonide 400 micrograms/12 h for 4 weeks and 200 micrograms/12 h for 4 more weeks
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 6841631

Group type: EXPERIMENTAL
Intervention: Clinicians who received a warning regarding the error of assessing art ability
Number of subjects: 64

Group type: COMPARATOR
Intervention: Clinicians who did not receive a warning regarding the error of assessing art ability
Number of subjects: 64
Study: 31918739

Group type: EXPERIMENTAL
Intervention: Telephone-assisted self-help (TASH) intervention for parents
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Parent management and preschool teacher training
Number of subjects: 200

Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 200
Study: 31115348

Group type: EXPERIMENTAL
Intervention: Tumaini smartphone game intervention
Number of subjects: 60